Council of Europe tackles drug industry’s “less noble” sideBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5474 (Published 13 October 2015) Cite this as: BMJ 2015;351:h5474
- Rory Watson
Parliamentarians from 47 European countries have overwhelmingly given their backing to moves for more openness in drug companies’ relationships with the health sector. In particular, they want the companies to make all links with the sector publicly available and to disclose the real costs of researching and developing new medicines.
The demands were contained in a resolution adopted by the Council of Europe’s parliamentary assembly on 29 September and directed at national governments. Although not legally binding, the resolution carries political and moral weight, as it was approved by nationally elected politicians across the continent by 118 votes to eight, with just seven abstentions.
Liliane Maury Pasquier, a Swiss socialist MP …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial